Context
Inotrem is a leading biotechnology company specialized in the development of immunotherapies for acute and chronic inflammatory diseases.
It has a seasoned management team with complementary experiences in large pharma and biotech companies.
Inotrem’s lead candidate, nangibotide, is a Phase IIb compound designed to treat septic shock, the ultimate complication of sepsis, with a mortality rate of 35% in developed countries.
It has the potential to become the first mechanism-based therapy approved in a challenging indication.
Bryan, Garnier & Co was retained to lead a Series B round to finance Phase IIb trial and nangibotide companion diagnostic final development.
The proceeds will also allow Inotrem to further leverage its platform to address chronic inflammatory diseases.
About Inotrem
Inotrem S.A. has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr Marc Derive.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Sole Financial Advisor to Inotrem on its EUR 44 million Series B Fundraising
Bryan, Garnier & Co acted as Sole Financial Advisor to Inotrem on its fundraising process.
A broad and international process targeting both specialist and generalist funds was run across Europe, the US and China.
The investment round was led by the renowned American venture capital firm Morningside and joined by Invus and Fountain Healthcare, two well-established healthcare specialist investors. Historical shareholders Andera Partners, Sofinnova and BiomedInvest also took part in the placement reaffirming their support in Inotrem.
Bryan, Garnier & Co’s deep healthcare industry expertise combined with 20 years of experience in leading financing rounds, enabled Inotrem to secure an optimal transaction to pursue its clinical and operational development .
Share